Population pharmacokinetics and exposure-clinical outcome relationship of remdesivir major metabolite GS‐441524 in patients with moderate and severe COVID‐19

Abstract Although remdesivir, a prodrug of nucleoside analog (GS‐441524), has demonstrated clinical benefits in coronavirus disease 2019 (COVID‐19) treatment, its pharmacokinetics (PKs) in patients with COVID‐19 remain poorly understood. Therefore, in this study, the PKs of remdesivir and its major...

詳細記述

保存先:
書誌詳細
主要な著者: Ryo Tamura (著者), Kei Irie (著者), Atsushi Nakagawa (著者), Hirohito Muroi (著者), Masaaki Eto (著者), Hiroaki Ikesue (著者), Nobuyuki Muroi (著者), Shoji Fukushima (著者), Keisuke Tomii (著者), Tohru Hashida (著者)
フォーマット: 図書
出版事項: Wiley, 2023-04-01T00:00:00Z.
主題:
オンライン・アクセス:Connect to this object online.
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

インターネット

Connect to this object online.

3rd Floor Main Library

予約・返却請求 3rd Floor Main Library
請求記号: A1234.567
所蔵 1 利用可